J Kriz1, C Baues2, R Engenhart-Cabillic3, U Haverkamp1, K Herfarth4, P Lukas5, H Schmidberger6, S Marnitz-Schulze2, M Fuchs7, A Engert7, H T Eich8. 1. Department of Radiation Oncology, University of Muenster, Albert-Schweitzer Campus 1, Gebäude 1 A, 48419, Muenster, Germany. 2. Department of Radiation Oncology, University of Cologne, Köln, Deutschland. 3. Department of Radiation Oncology, University of Marburg, Marburg, Deutschland. 4. Department of Radiation Oncology, University of Heidelberg, Heidelberg, Deutschland. 5. Department of Radiation Oncology, University of Innsbruck, Innsbruck, Deutschland. 6. Department of Radiation Oncology, University of Mainz, Mainz, Deutschland. 7. Department of Internal Medicine, University of Cologne, Köln, Deutschland. 8. Department of Radiation Oncology, University of Muenster, Albert-Schweitzer Campus 1, Gebäude 1 A, 48419, Muenster, Germany. hans.eich@ukmuenster.de.
Abstract
INTRODUCTION: Field design changed substantially from extended-field RT (EF-RT) to involved-field RT (IF-RT) and now to involved-node RT (IN-RT) and involved-site RT (IS-RT) as well as treatment techniques in radiotherapy (RT) of Hodgkin's lymphoma (HL). The purpose of this article is to demonstrate the establishment of a quality assurance program (QAP) including modern RT techniques and field designs within the German Hodgkin Study Group (GHSG). METHODS: In the era of modern conformal RT, this QAP had to be fundamentally adapted and a new evaluation process has been intensively discussed by the radiotherapeutic expert panel of the GHSG. RESULTS: The expert panel developed guidelines and criteria to analyse "modern" field designs and treatment techniques. This work is based on a dataset of 11 patients treated within the sixth study generation (HD16-17). CONCLUSION: To develop a QAP of "modern RT", the expert panel defined criteria for analysing current RT procedures. The consensus of a modified QAP in ongoing and future trials is presented. With this schedule, the QAP of the GHSG could serve as a model for other study groups.
INTRODUCTION: Field design changed substantially from extended-field RT (EF-RT) to involved-field RT (IF-RT) and now to involved-node RT (IN-RT) and involved-site RT (IS-RT) as well as treatment techniques in radiotherapy (RT) of Hodgkin's lymphoma (HL). The purpose of this article is to demonstrate the establishment of a quality assurance program (QAP) including modern RT techniques and field designs within the German Hodgkin Study Group (GHSG). METHODS: In the era of modern conformal RT, this QAP had to be fundamentally adapted and a new evaluation process has been intensively discussed by the radiotherapeutic expert panel of the GHSG. RESULTS: The expert panel developed guidelines and criteria to analyse "modern" field designs and treatment techniques. This work is based on a dataset of 11 patients treated within the sixth study generation (HD16-17). CONCLUSION: To develop a QAP of "modern RT", the expert panel defined criteria for analysing current RT procedures. The consensus of a modified QAP in ongoing and future trials is presented. With this schedule, the QAP of the GHSG could serve as a model for other study groups.
Entities:
Keywords:
Intensity-modulated radiotherapy; Lymphoma; Organs at risk; Sequelae; Treatment failure
Authors: Julia Koeck; Yasser Abo-Madyan; Frank Lohr; Florian Stieler; Jan Kriz; Rolf-Peter Mueller; Frederik Wenz; Hans Theodor Eich Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-11 Impact factor: 7.038
Authors: Jan Kriz; Gabriele Reinartz; Markus Dietlein; Carsten Kobe; Georg Kuhnert; Heinz Haverkamp; Uwe Haverkamp; Rita Engenhart-Cabillic; Klaus Herfarth; Peter Lukas; Heinz Schmidberger; Susanne Staar; Kira Hegerfeld; Christian Baues; Andreas Engert; Hans Theodor Eich Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-01 Impact factor: 7.038
Authors: Lena Specht; Joachim Yahalom; Tim Illidge; Anne Kiil Berthelsen; Louis S Constine; Hans Theodor Eich; Theodore Girinsky; Richard T Hoppe; Peter Mauch; N George Mikhaeel; Andrea Ng Journal: Int J Radiat Oncol Biol Phys Date: 2013-06-18 Impact factor: 7.038
Authors: Hans Theodor Eich; Volker Diehl; Helen Görgen; Thomas Pabst; Jana Markova; Jürgen Debus; Anthony Ho; Bernd Dörken; Andreas Rank; Anca-Ligia Grosu; Thomas Wiegel; Johann Hinrich Karstens; Richard Greil; Normann Willich; Heinz Schmidberger; Hartmut Döhner; Peter Borchmann; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Andreas Engert Journal: J Clin Oncol Date: 2010-08-16 Impact factor: 44.544
Authors: Andreas Engert; Petra Schiller; Andreas Josting; Richard Herrmann; Peter Koch; Markus Sieber; Friederike Boissevain; Maike De Wit; Jorg Mezger; Eckhart Duhmke; Normann Willich; Rolf-Peter Muller; Bernhard F Schmidt; Helmut Renner; Hans Konrad Muller-Hermelink; Beate Pfistner; Jurgen Wolf; Dirk Hasenclever; Markus Loffler; Volker Diehl Journal: J Clin Oncol Date: 2003-08-11 Impact factor: 44.544
Authors: Bhishamjit S Chera; Christina Rodriguez; Christopher G Morris; Debbie Louis; Daniel Yeung; Zuofeng Li; Nancy P Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-20 Impact factor: 7.038
Authors: C Baues; R Semrau; U S Gaipl; P J Bröckelmann; J Rosenbrock; A Engert; S Marnitz Journal: Strahlenther Onkol Date: 2016-10-04 Impact factor: 3.621
Authors: Eva Holzhäuser; Maximilian Berlin; Daniel Wollschläger; Thomas Bezold; Arnulf Mayer; Georg Heß; Heinz Schmidberger Journal: Strahlenther Onkol Date: 2017-07-26 Impact factor: 3.621